Ardelyx, Inc. (ARDX)
- Previous Close
6.39 - Open
6.48 - Bid 6.41 x 800
- Ask 6.45 x 1500
- Day's Range
6.39 - 6.66 - 52 Week Range
3.16 - 10.13 - Volume
5,440,670 - Avg. Volume
5,542,791 - Market Cap (intraday)
1.496B - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
-- - EPS (TTM)
-0.30 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.65
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
www.ardelyx.comRecent News: ARDX
Performance Overview: ARDX
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARDX
Valuation Measures
Market Cap
1.50B
Enterprise Value
1.37B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.33
Price/Book (mrq)
8.97
Enterprise Value/Revenue
10.99
Enterprise Value/EBITDA
-24.71
Financial Highlights
Profitability and Income Statement
Profit Margin
-53.08%
Return on Assets (ttm)
-16.22%
Return on Equity (ttm)
-49.83%
Revenue (ttm)
124.46M
Net Income Avi to Common (ttm)
-66.07M
Diluted EPS (ttm)
-0.30
Balance Sheet and Cash Flow
Total Cash (mrq)
184.3M
Total Debt/Equity (mrq)
45.66%
Levered Free Cash Flow (ttm)
-51.77M